




Received January 9, 2012; Last revision June 18, 2012; 
Accepted June 19, 2012
A supplemental appendix to this article is published electroni-
cally only at http://jdr.sagepub.com/supplemental.
© International & American Associations for Dental Research
D.J. Taxman1,2*‡, Y. Lei1,2,3,5*,  
S. Zhang3,4, E. Holley-Guthrie1,2,  
S. Offenbacher3,4¥, and J.P.-Y. Ting1,2¥
1Department of Microbiology and Immunology, School of 
Medicine; 2Lineberger Comprehensive Cancer Center; 3North 
Carolina Oral Health Institute, School of Dentistry; 
4Department of Periodontology, School of Dentistry; 
University of North Carolina, Chapel Hill, NC, USA;  5Present 
address: Oral and Maxillofacial Pathology, University of 
Pittsburgh Medical Center, Pittsburgh, PA, USA; *authors 
contributing equally to this work as first authors; and ¥authors 
contributing equally to this work as last authors; ‡correspond-
ing author, debra_taxman@med.unc.edu
J Dent Res 91(9):877-882, 2012
AbstrAct
Levels of prostaglandin E2 (PGE2) and its processing 
enzyme, prostaglandin-endoperoxide-synthase-2/ 
cyclooxygenase-2 (PTGS2/COX-2), are elevated in 
actively progressing periodontal lesions, but suppressed 
in chronic disease. COX-2 expression is regulated 
through inflammatory signaling that converges on the 
mitogen-activated protein kinase (MAPK) pathway. 
Emerging evidence suggests a role for the inflammatory 
adaptor protein, ASC/Pycard, in MAPK activation. We 
postulated that ASC may represent a mediator of the 
MAPK-mediated regulatory network of PGE2 production. 
Using RNAi-mediated gene silencing, we demonstrated 
that ASC regulates COX-2 expression and PGE2 produc-
tion in THP1 monocytic cells following infection with 
Porphyromonas gingivalis (Pg). Production of PGE2 did 
not require the inflammasome adaptor function of ASC, 
but was dependent on MAPK activation. Furthermore, 
the MAP kinase kinase kinase CARD domain-contain-
ing protein RIPK2 was induced by Pg in an ASC-
dependent manner. Reduced ASC and RIPK2 levels 
were revealed by orthogonal comparison of the expres-
sion of the RIPK family in ASC-deficient THP1 cells 
with that in chronic periodontitis patients. We show that 
pharmacological inhibition of RIPK2 represses PGE2 
secretion, and RNAi-mediated silencing of RIPK2 leads 
to diminished MAPK activation and PGE2 secretion. 
These findings identify a novel ASC-RIPK2 axis in the 
generation of PGE2 that is repressed in patients diag-
nosed with chronic adult periodontitis.
KEY WOrDs: periodontal disease, COX-2, PTGS2, 
Porphyromonas gingivalis, ASC, RIPK2. 
IntrODuctIOn
From 5 to 20% of the population is affected by severe periodontitis (Petersen et al., 2005), a condition that is the leading cause of tooth loss in adults and 
increases risks for several major systemic diseases, including coronary heart 
disease, atherosclerosis, rheumatoid arthritis, cancer, and preterm birth (Lamster 
et al., 2008; Hayashi et al., 2010). In this study, we abided by the 1999 World 
Workshop for the Classification of Periodontal Diseases and Conditions to 
define the chronic periodontitis condition (Caton and Armitage, 1999). The 
establishment of chronic periodontitis entails multiple cycles of progression and 
remission mediated by the modulation of pro-inflammatory signaling activi-
ties (Demmer and Papapanou, 2010). Identification of underlying inflamma-
tory mechanisms of periodontal disease holds promise for the development 
of novel targets of periodontal treatment. One inflammatory mediator that has 
spanned the interface between bacterial infection and periodontal tissue damage 
is prostaglandin E2 (PGE2; Offenbacher et al., 1993; Noguchi and Ishikawa, 
2007). Although the correlation between PGE2 levels in gingival crevicular 
fluid (GCF) and clinical parameters of periodontitis such as periodontal attach-
ment loss and signs of bleeding on probing has been documented (Noguchi 
and Ishikawa, 2007; Zhong et al., 2007; Zhang et al., 2011), it is critical to 
interpret the value of PGE2 levels in periodontitis progression in a stage-sensi-
tive fashion. For example, acute challenge of rat periodontal tissue with lipo-
polysaccharide (LPS) induces the expression of prostaglandin-endoperoxide 
synthase-2/cyclooxygenase-2 (PTGS2, or COX-2), which is responsible for the 
biosynthesis of PGE2 (Miyauchi et al., 2004). However, cumulative damage 
of periodontal tissue is negatively associated with PGE2 levels in GCF (Zhong 
et al., 2007). One possible mechanism for the reduced PGE2 expression during 
chronic disease involves epigenetic modification leading to decreased COX-2 
mRNA synthesis. Recently, Zhang et al. reported hypermethylation at the COX-
2 promoter, which was associated with squelched PGE2 mRNA expression and 
lowered PGE2 production in chronic inflamed tissues (Zhang et al., 2011). The 
expression of COX-2 is known to be regulated by extracellular stimuli through 
a variety of inflammatory signaling pathways that converge on the mitogen-
activated protein kinase (MAPK) pathway (Tsatsanis et al., 2006). However, the 
molecular machinery that is involved in MAPK-mediated regulation of PGE2 
generation remains poorly defined.
Emerging evidence suggests that ASC (apoptosis-associated speck-like 
protein containing a CARD), an important mediator of host pro-inflammatory 
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responses, is pivotal in mediating NF-κB and MAPK signaling, 
and cytokine and chemokine expression in THP1 monocytic 
cells following infection with Porphyromonas gingivalis (Pg) 
(Taxman et al., 2006b, 2011). Pg is a bacterial pathogen that has 
been unequivocally shown to mediate tissue destruction and 
trigger host inflammatory responses in chronic periodontitis 
(Hayashi et al., 2010). We postulated that PGE2 production may 
be regulated through ASC-dependent activation of MAPK. A 
MAPK pathway regulator that associates with ASC via its 
CARD (caspase activation and recruit domain), RIPK2, belongs 
to the RIP family of kinases (Receptor-Interacting serine/threo-
nine-Protein Kinase); (Navas et al., 1999; Sarkar et al., 2006). 
The RIPK family acts as integrators of cellular stress responses 
for a diverse array of stimuli, including pathogenic infection, 
inflammation, and DNA damage (Meylan and Tschopp, 2005). 
We hypothesized that RIPK2 may mediate ASC-dependent 
MAPK and PGE2 activation.
MAtErIAls & MEthODs
bacterial culture
We used the A7436 strain, because of its established immunos-
timulatory effect on monocytic cells (Taxman et al., 2006b, 
2011; Huang et al., 2009) and virulence properties (Genco 
et al., 1991). Pg strain A7436 was grown anaerobically in Wilkins-
Chalgren broth to late-exponential phase (OD 0.8 to 1.2 at 600 nm). 
Frozen aliquots were stored in media containing 10% glycerol at 
-80°C and thawed immediately prior to use. The enumeration and 
viability of bacteria were verified by serial plating.
cell culture and Generation of Knockdown cell lines
THP1 monocytic cells (ATCC, Manassas, VA, USA) were cul-
tured in RPMI, 10% FCS. THP1 cell lines bearing a short hairpin 
RNA (shRNA) for RNA interference (RNAi)-mediated gene 
silencing of ASC (shASC#1 and shASC#2) or a control, non-
silencing shRNA (shCTRL) were generated with retroviral vec-
tors and have been described previously (Taxman et al., 2006a,b, 
2011). Lentiviral shRNA vectors for gene silencing of RIPK2 and 
GFP were from the TRC Collection (Open Biosystems, Lafayette, 
CO, USA). Lentivirus was packaged in 293T cells with vectors 
pMD2.G and psPAX2 (Addgene plasmids 12259 and 12260, 
Cambridge, MA, USA). Cells were selected in 1 μg/mL puromy-
cin for 2 wks, and JRed marker expression was confirmed by 
FACS. Bacterial infections (106 cells/mL in 10% FCS) were at 10 
MOI unless otherwise indicated. Where indicated, cells were pre-
treated for 1 hr with DMSO solvent control (Sigma-Aldrich, St. 
Louis, MO, USA), 10 μg/mL Anakinra/Kineret® (Amgen, 
Thousand Oaks, CA, USA), 10 μM YVAD-cmk (Clontech, 
Mountain View, CA, USA), 10 μM U0126 (Promega Corporation, 
Madison, WI, USA), 1-10 μM PP2, SB202190, or SB203580 (LC 
Laboratories, Woburn, MA, USA).
Patient Information
Demographic information for the 17 participants included in the 
microarray studies and 30 participants included in the real-time 
PCR analyses are detailed in the Results section. The study was 
approved by the Institutional Review Board of the University of 
North Carolina at Chapel Hill. Subjects were excluded if they: 
(1) used either antibiotics or non-steroidal anti-inflammatory 
medications within 1 mo of the periodontal treatment; or (2) had 
a medical history significant for systemic diseases and were 
actively participating in the treatment thereof. Periodontal eval-
uation included probing depths, clinical attachment level, and 
bleeding on probing at 6 sites per tooth. Gingival tissue was 
sampled at the interproximal region. Specimens were treated 
with RNAlater (Qiagen, Valencia, CA, USA) overnight at 4ºC 
and stored at -80ºC.
Microarray Analysis
Microarray analysis of triplicate samples of Pg-infected shC-
TRL and shASC#1 THP1 cells was performed at the Duke 
Microarray facility with 34,000 spot custom chips based on the 
version 3 Human oligo set (Operon Biotechnologies, Inc., 
Huntsville, AL, USA), and has been described previously 
(Taxman et al., 2011). Microarray analyses of gingival biopsies 
of the 17 individual study participants were performed individu-
ally with the GeneChip® Human Gene 1.0 ST Array covering 
28,869 genes (Affymetrix, Santa Clara, CA, USA). Scanning 
was performed with the GeneChip Scanner 3000 7G platform 
(Affymetrix, Santa Clara, CA, USA). Gene expression was ana-
lyzed in GeneSpring 11 for interpretation of fold changes and 
statistical validation.
real-time Pcr
ASC mRNA levels were quantified with Taqman Assays on 
Demand® (Applied Biosystems, Carlsbad, CA, USA). COX-2 
and RIP2 mRNA were measured by SYBR-based quantitative 
real-time PCR as described previously (Taxman et al., 2006a,b). 
The primer sequences were as follows: COX-2-GCCTGCT 
TGTCTGGAACAAC; TGGTGCCTGGTCTGATGATG; RIP2-
CTGGCACTGTGTCGTCCGCC;TCTTTCACTGTCGAGCA
GCGGAG, 18s-CGGCTACCACATCCAAGG; and GCTG 
CTGGCACCAGACTT. All values were standardized to 18s 
rRNA expression.
Western blot Analysis
Western blot analysis was performed as described previously 
(Taxman et al., 2006b), with antibodies against RIP2 (Cell 
Signaling Technology #4982, Danvers, MA, USA), pERK 
(Santa Cruz Biotechnology, Inc. #sc-7383, Santa Cruz, CA, 
USA), pJNK (Cell Signaling Technology #4668, Danvers, MA, 
USA), and GAPDH (Millipore # MAB374, Billerica, MA, 
USA). Results are representative of at least 3 experiments.
PGE2 ElIsA Analysis
Supernatants were collected 18 to 24 hrs following infection 
with Pg. Quantification of PGE2 levels was performed 
by ELISA (R&D Systems #KGE004B, Minneapolis, MN, 
USA).
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rEsults
Asc regulates COX-2 Expression and PGE2 Production 
in thP1 Monocytic cells following Infection with Pg
Monocytes are one of the primary contributors of cytokines and 
chemokines in periodontal degeneration (Page, 1992). We have 
established the THP1 monocytic cell line as a useful model to 
study the interaction between the host and Pg infection (Taxman 
et al., 2006b, 2011; Huang et al., 2009). To directly assess the 
function of ASC in regulating PGE2 production, we constructed 
THP1 cell lines with reduced ASC expression using 2 different 
short hairpin RNAs: shRNA#1 (> 90% knockdown) and 
shASC#2 (~70% knockdown; Taxman et al., 2006a). Levels of 
COX-2 mRNA and secreted PGE2 were significantly reduced 
following Pg infection in both of the ASC knockdown cell lines 
as compared with either non-transduced cells (THP1) or cells 
bearing an empty vector (shCTRL) (Figs. 1A, 1B).
ASC is known as an adaptor in the inflammasome complex, 
which is critical in the processing of IL-1β following pathogenic 
or environmental challenges (Broz and Monack, 2011). To test 
whether IL-1β signaling is required for the induction of PGE2, 
we pre-treated THP1 cells with the IL-1β receptor antagonist 
Kineret® at a dose shown to obliterate signaling (Taxman et al., 
2006b). Induction of PGE2 was unaffected by Kineret
®, suggest-
ing that PGE2 induction is IL-1β-independent (Fig. 1C). PGE2 
induction was also unaffected by YVAD-cmk, a specific inhibi-
tor of caspase-1, the activation of which is absolutely required 
for IL-1β maturation in THP1 cells following infection with Pg 
(Taxman et al., 2006b; Huang et al., 2009).
We and others recently demonstrated that ASC mediates the 
activation of MAPK independent of the inflammasome 
(Hasegawa et al., 2009; Taxman et al., 2011). Therefore, we 
postulated that the ASC-dependent activation of PGE2 may be 
regulated by MAPK activity. To test this possibility, we treated 
THP1 cells with U0126, an inhibitor of the ERK pathway, prior 
to infection with Pg (Fig. 1C, last lane). U0126 nearly abolished 
PGE2 protein production. Collectively, these results suggest that 
ASC is essential for Pg-induced PGE2 production, and that its 
function in activating PGE2 involves MAPK activation indepen-
dent of its role in the inflammasome.
Asc Modulates the Expression of the MAP Kinase 
kinase kinase rIPK2
Homotypic CARD:CARD associations are essential for a host 
of inflammatory signaling cascades (Bouchier-Hayes and 
Martin, 2004). A search for CARD-containing proteins with 
signaling activity upstream of the MAPKs led us to consider a 
possible role for RIPK2 in PGE2 regulation. RIPK2 directly 
associates with ASC upon activation with LPS (Sarkar et al., 
2006). As one of the primary pathogens that triggers periodontal 
inflammation and tissue degeneration, Pg potently induced 


























































































Figure 1. Activation of ASC-dependent PGE2 in THP1 monocytic cells 
following infection with Pg. (A) Expression of COX-2 mRNA in non-
transduced THP1 cells and THP1 cells expressing a control shRNA 
(shCTRL) or 1 of 2 shRNA directed against ASC (shASC#1 and 
shASC#2). Expression levels were determined by real-time PCR of RNA 
isolated 2 hrs following treatment of cells with 10 MOI Pg. Results are 
normalized to the expression of 18s rRNA and expressed as averages 
with standard deviation for duplicates. Results are representative of 3 
independent experiments. *p < 0.05. (b) Production of PGE2 following 
18-hour infection of control and ASC knockdown THP1 cell lines with 10 
MOI Pg. PGE2 levels were measured by ELISA. Results are expressed as 
averages and standard deviation of 3 specimens, and represent 3 
independent experiments. *p < 0.05. (c) ELISA analysis for PGE2 in 
supernatants from THP1 cell cultures prior to or following 18-hour 
incubation with Pg. Where indicated, cells were pre-treated with the 
IL-1β receptor antagonist Kineret®, the caspase-1 inhibitor YVAD-cmk, or 
the ERK inhibitor U0126. * indicates statistical difference from Pg-
infected THP1 control sample as determined by t test (p < 0.05). Results 

















0 0.5 1 2
shCTRL shASC


















Figure 2. Orthogonal comparison of RIP kinase expression levels in 
ASC-deficient THP1 cells and in chronic periodontitis patients. (A) 
Western blot of RIPK2 protein levels in THP1 cells following an extended 
time-course of infection with Pg. (b) Western blot of RIPK2 protein levels 
in shCTRL and shASC#1 THP1 cells following a time-course of infection 
with Pg. GAPDH is shown as an internal control. Results are representative 
of 3 independent experiments. (c) Levels of RIPK1, RIPK2, and RIPK3 
mRNA in control vs. ASC knockdown THP1 cells 2 hrs following 
infection with Pg. RIPK2 was reduced 2.4-fold in ASC knockdown cells 
(p value = 1.092 x 10-4; Q value = 3.276 x 10-4), as determined by 
microarray analysis. (D) Levels of RIP1, RIP2, and RIP3 mRNA in chronic 
periodontitis patients vs. healthy control individuals, as determined by 
microarray analysis. RIP2 was 1.5-fold lower in the patient sample 
population (p value = 0.011; Q value = 0.032).
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RIPK2 protein expression (Fig 2A). 
Furthermore, repression of ASC strongly 
mitigated this induction (Fig. 2B). To 
assess the specificity of this repression 
for RIPK2, we performed microarray 
analysis using RNA from Pg-infected 
shCTRL and shASC THP1 cells. RIPK2 
expression was reduced 2.4-fold in Pg-
infected ASC knockdown cells (p value = 
1.092 × 10-4; corrected p value = 3.276 × 
10-4) (Fig. 2C), whereas 2 other members 
of the RIPK family of MAPK-activating 
proteins (Meylan and Tschopp, 2005), 
RIPK1 and RIPK3, were minimally 
changed.
ASC and RIPK2 Expression Is 
reduced in Gingival tissues 
from Individuals with chronic 
Periodontitis
We performed microarray analysis to 
assess whether levels of RIPK2 may be 
regulated in vivo. RNA was collected 
from gingival biopsies from seven 
patients with chronic adult periodontitis 
and ten healthy control individuals 
(Appendix Fig.). Similar to our findings 
from Pg-infected THP1 ASC knockdown 
cells (Fig. 2C), RIPK2 was reduced 1.5-
fold in chronic periodontitis gingival tis-
sue (p value = 0.0108; corrected p value 
= 0.0324), while RIPK1 and RIPK3 
showed minimal change (Fig. 2D).
To verify these findings, we recruited 
17 chronic periodontitis patients and 13 
healthy volunteers. Patients and control 
individuals were age-matched (p > 0.1). 
Those with chronic periodontitis demon-
strated marked increases in probing 
depth, clinical attachment loss, and bone 
loss as compared with healthy control 
individuals (Fig. 3A). Consistent with 
our previous study (Zhang et al., 2011), 
COX-2 expression was repressed in 
chronically inflamed gingival tissue 
(Fig. 3B). Furthermore, ASC and RIPK2 
were also reduced. These findings are 
consistent with a potential role for ASC 
in modulating RIPK2 expression both in 
vitro and in vivo.
rIPK2 Is required for MAPK 
Activation and PGE2 Induction by Pg
We utilized two approaches to determine 
directly whether RIPK2 regulates PGE2 
induction. First, THP1 cells were treated 
with a panel of pharmacological agents 
A
B






Group (n=17) p value
Age (yrs) (mean ±SD) 39.38 ±14.05  46.53 ±12.01                   0.145  
Gender  
  Males/Females                    3/10                   8/9                    0.26  
Probing  
Depth (mm)  
(mean ±SD) 
           2.23 ±0.93             5.71 ±1.21               <0.0001  
Clinical Attachment  
Loss (mm)  
(mean ±SD) 
Smoking status  
(Never/Ex/Current smoker)  
Alveolar bone loss 
          0.85 ±0.90  
 9/4/0  
   No                      
           4.53 ±1.74  
              8/3/6  
                Yes
             <0.0001  





















Figure 3. ASC and RIPK2 are repressed in the gingival tissue of chronic adult periodontitis 
patients. (A) Demographic profile of age-matched 13 healthy volunteers and 17 patients. All 
patients demonstrated elevated probing depth, clinical attachment loss, and moderate to 
severe bone loss. (b) Relative mRNA fold change of COX-2, ASC, and RIPK2 in gingival 
tissues from 13 healthy volunteers and 17 chronic adult periodontitis patients.























































Figure 4. RIPK2 is required for the activation of PGE2 production following infection with Pg. (A) 
Pharmacological inhibition of RIPK2 leads to reduced PGE2 production. ELISA analysis of 
supernatants was performed prior to or following 18-hour infection with Pg. Where indicated, cells 
were pre-treated with the carrier DMSO or the RIPK2 inhibitors PP2, SB202190, or SB203580 at 
a concentration of 1 and 10 µM. Results are expressed as average with standard deviation of 
duplicates, and represent 2 independent experiments.* p < 0.05. (b) Western analysis of RIPK2, 
p-ERK, and p-JNK protein levels in control GFP knockdown cells (shGFP) and RIPK2 knockdown 
cells (shRIP2) following a time-course of infection with Pg. Results are representative of 3 
independent experiments. (c) ELISA of PGE2 levels in supernatants of shGFP and shRIP2 cells 
following 18-hour infection with Pg at 5 or 20 MOI. Results are expressed as average with 
standard deviation of duplicates, and represent 3 independent experiments. * p < 0.05. (D) Model 
for ASC and RIPK2-dependent activation of PGE2 production following Pg infection.
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known to inhibit RIPK2 kinase function (Bain et al., 2007) prior 
to infection with Pg. A dose-dependent reduction in PGE2 was 
observed for each of these inhibitors (Fig. 4A). Second, RIPK2 
expression was inhibited by RNAi-mediated gene silencing. The 
activation of the MAPKs, ERK, and JNK in RIPK2-deficient 
cells was markedly reduced, verifying the role of RIPK2 as an 
upstream activator of these signaling molecules (Fig 4B). RIPK2 
gene silencing also led to the reduced production of PGE2 follow-
ing infection with Pg at 2 different MOIs (Fig 4C). The findings 
collectively demonstrate that RIPK2 mediates PGE2 production in 
response to a pathogen mediating periodontal destruction.
DIscussIOn
The progression of chronic adult periodontitis is featured by 
cycles of exacerbation and remission, eventually leading to irre-
versible periodontal structure destruction. A key to the develop-
ment of novel treatment is the identification of critical 
inflammatory mediators that are regulated during these cycles 
and targeting of these mediators with small bioactive pharmaco-
logic molecules. Initial studies suggested that the up-regulation 
of PGE2 is associated with bone loss in humans and in animal 
models and that COX-2 inhibitors may reduce bone loss 
(Offenbacher et al., 1993; Noguchi and Ishikawa, 2007). 
However, the ligature-induced periodontitis model features rap-
idly progressing periodontal inflammation, which more aptly 
reflects disease exacerbation, but not remission stages associ-
ated with human chronic adult periodontitis. In addition, for 
affected individuals, shallow sites are more likely to be respon-
sible for the progression of periodontitis, whereas deep sites 
display lower levels of PGE2 (Beck et al., 1997). Indeed, previ-
ous studies have suggested that COX-2 levels are lower in 
chronically inflamed gingival tissue (Zhong et al., 2007; Zhang 
et al., 2011).
The regulation of COX-2 is dependent upon both genetic and 
epigenetic mechanisms. In addition to a hypermethylation pat-
tern at the COX-2 promoter region that dampens the production 
of COX-2 mRNA (Zhang et al., 2011), the present study identi-
fied a novel mechanism controlling the production of PGE2 that 
could have relevance in the pathogenesis of periodontitis (Fig. 
4D). When a periodontal pathogen such as Pg engages the host 
monocytic cells, ASC translates the insult into MAPK activation 
in a RIPK2-dependent fashion. Despite the high structural simi-
larity among RIPKs, our study suggested a specificity of RIPK2 
in mediating the inflammatory responses of periodontal tissue. 
Recent evidence reveals a central role of RIPK2 in mediating 
innate immune activation through association with NOD2 
(Tigno-Aranjuez et al., 2010). NOD2 is an NLR (nucleotide-
binding, leucine-rich repeats) protein that is associated with 
Crohn’s and other chronic auto-inflammatory diseases 
(Borzutzky et al., 2010). Notably, NOD2 has also been reported 
to have a critical role in the sensing of periodontal pathogens 
(Okugawa et al., 2009).
The pattern of ASC-mediated, RIPK2-dependent PGE2 produc-
tion in THP-1 cells in response to Pg challenge in our study con-
ceptually agrees with that observed in gingival tissues from patients 
with chronic adult periodontitis. The establishment of chronic 
periodontitis, however, is the cumulative outcome of the interaction 
between the host and multiple pathogens; thus, we chose Pg as 
a simplified model pathogen to highlight the significance of the 
ASC-RIPK2 axis. Consistent with our findings, a prior study 
showed reduced ASC levels upon Pg infection in Mono-Mac-6, 
a monocytic cell line (Bostanci et al., 2009); however, in the 
same study, differences were not observed in ASC in healthy vs. 
diseased gingival tissues. Given that PGE2 is differentially regu-
lated during disease remission/exacerbation (Zhong et al., 2007; 
Zhang et al., 2011), differences in disease stage could explain 
this discrepancy between our studies. In addition, the expression 
profiles of apoptotic and inflammatory signaling genes for gin-
gival tissues are known to be highly age-dependent (Gonzalez 
et al., 2011). Finally, differences in the timing of biopsies, i.e., 
before or after non-surgical periodontal treatment, could con-
tribute to the observed discrepancy. It is widely known that 
microarray can squelch differences between samples; however, 
our results were additionally verified by real-time PCR. Future 
study is necessary to delineate the role of RIPK2 in the progres-
sion stage of periodontitis development and to evaluate whether 
RIPK2 inhibitors might prevent chronic disease progression by 
stabilizing PGE2 levels during periods of exacerbation.
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